300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Retail
Oil and Gas
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Gaming
Agriculture (AgTech)
Facebook
Blockchain
Social Network
B2B
Medical Device
Education
Sports
Wellness
Biotechnology
Automotive
eSports
Legal
Software
Renewable Energy
Crowdfunding
Venture Capital
Recruiting
Web3
Medical
Theatre
Climate
LGBT
Cannabis
Social
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Infrastructure
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
Beauty
FinTech
Finance
Digital Media
Social Media
Fashion
Financial Services
Franchise
Android
Non Profit
Internet
Mobile Advertising
Proptech
Impact
Sustainability
Enterprise
Hardware
Biotech
Transportation
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Gibraltar
Burkina Faso
Africa
Singapore
Brazil
LATAM
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Cameroon
Guernsey
China
Colombia
Armenia
Costa Rica
Czech Republic
Kenya
Marshall Islands
Kuwait
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Ireland
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Bangladesh
Barbados
Belgium
Europe
Jordan
Qatar
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Angola
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Cyprus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Perseverance Capital Management, VC Fund

Perseverance Capital Management

VC Fund

Los Angeles, United States

Perseverance Capital Management is an asset management firm investing in the healthcare sector.It is a long-term investor and believes that it is critical to be a value-added investor by actively working with portfolio company management teams to help build market-leading companies. They are committed to building businesses through deepcollaborative partnerships with world-class scientists, clinicians, outstanding entrepreneurs, and management teams. The investment objective of Perseverance is to not only achieve a long-term capital appreciation for their investors but also to partner, build, operate, and finance companies that have the potential to make a difference in patients' lives.The Los Angeles, California-headquartered firm was founded in 2013.

Total investments:
6
Last investment:
Lead investor:
0%

Last updated:

Industries Perseverance Capital Management invests in

BiotechnologyMedicalHealth CareMedical DeviceBlockchain

Stages Perseverance Capital Management invests in

SeedSeries CSeries BSeries D

Countries Perseverance Capital Management invests in

United StatesMexico

Round sizes

Seed $5M–$10M

Round size

Seed
$5M–$10M

Investment Focus

Industry

  • Biotechnology 3 (50%)
  • Medical 2 (33%)
  • Health Care 2 (33%)
  • Medical Device 2 (33%)
  • Blockchain 1 (17%)
See all 10 industries →

Stage

  • Seed 2 (33%)
  • Series C 2 (33%)
  • Series B 1 (17%)
  • Series D 1 (17%)

Country

  • United States 4 (67%)
  • Mexico 1 (17%)

Investments

CompanyDescriptionRoundLinks
Kailera Therapeutics is a clinical-stage biotechnology company that provides revolutionary therapies for treating obesity and related diseases. $600M / Series B / Oct 14, 2025
Galactic Holdings offers a series of digital finance products. $10M / Seed / Apr 17, 2023
MindRhythm is a medical device company focused on applying novel biometrics to stroke and concussion patients to improve diagnosis, triage and management. Their proprietary monitoring devices and communication platform provide novel and real-time visibility to life-threatening situations prehospital and in the operating room, allowing clinicians tointervene earlier and with better precision to prevent brain damage. $5M / Seed / Aug 24, 2021
CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies.CG Oncology acquired therights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial. $47M / Series D / Dec 10, 2020
CG Oncology formerly known as Cold Genesys is a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition, and development of novel immunotherapies. It specializes in the development of oncolytic immunotherapies to combat cancer, providing patients with new and impactful therapies.CG Oncology acquired therights to develop CG0070 from BioSante Pharmaceuticals (Nasdaq: BPAX). A phase I/IIa dose-escalating clinical trial has already completed in 35 patients with NMIBC. Cold Genesys is hopeful to get this therapy back into the clinical setting with the initiation of the proposed phase II/III trial. $22M / Series C / Mar 18, 2019
NxThera develops medical technologies to treat a variety of endourology conditions, including BPH. The company's technology platform utilizes a simple, minimally invasive, vapor therapy designed to measurably improve urinary flow and patient quality of life. BPH afflicts more than 32 million men in the United States. Series C

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Retail
Oil and Gas
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Gaming
Agriculture (AgTech)
Facebook
Blockchain
Social Network
B2B
Medical Device
Education
Sports
Wellness
Biotechnology
Automotive
eSports
Legal
Software
Renewable Energy
Crowdfunding
Venture Capital
Recruiting
Web3
Medical
Theatre
Climate
LGBT
Cannabis
Social
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Infrastructure
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
Beauty
FinTech
Finance
Digital Media
Social Media
Fashion
Financial Services
Franchise
Android
Non Profit
Internet
Mobile Advertising
Proptech
Impact
Sustainability
Enterprise
Hardware
Biotech
Transportation
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Gibraltar
Burkina Faso
Africa
Singapore
Brazil
LATAM
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Oman
Poland
Puerto Rico
Cameroon
Guernsey
China
Colombia
Armenia
Costa Rica
Czech Republic
Kenya
Marshall Islands
Kuwait
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Seychelles
Botswana
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Ireland
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Bangladesh
Barbados
Belgium
Europe
Jordan
Qatar
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Angola
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Cyprus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Perseverance Capital Management invest in?

Perseverance Capital Management invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Series C stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does Perseverance Capital Management invest in?

Perseverance Capital Management typically joins rounds of $5M–$10M at Seed. These are whole funding-round sizes, not Perseverance Capital Management's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Perseverance Capital Management took part in.

When did Perseverance Capital Management last invest?

The most recent investment recorded for Perseverance Capital Management closed in Oct 2025. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Perseverance Capital Management Perseverance Capital Management Find emails